Accepted for Publication: March 10, 2015.
Published Online: May 7, 2015. doi:10.1001/jamaoncol.2015.0829.
Study concept and design: Wang, P. W. Kantoff.
Acquisition, analysis, or interpretation of data: Harshman, Wang, Nakabayashi, Xie, Valenca, Werner, Yu, A. Kantoff, Sweeney, Mucci, Pomerantz, Lee, P. W. Kantoff.
Drafting of the manuscript: Harshman, Wang, Nakabayashi, Sweeney, Lee, P. W. Kantoff.
Critical revision of the manuscript for important intellectual content: Harshman, Wang, Xie, Valenca, Werner, Yu, A. Kantoff, Sweeney, Mucci, Pomerantz, Lee, P. W. Kantoff.
Statistical analysis: Wang, Xie, Mucci.
Obtained funding: P. W. Kantoff.
Administrative, technical, or material support: Harshman, Wang, Yu, Lee.
Study supervision: Lee, P. W. Kantoff.
Conflict of Interest Disclosures: Mr A. Kantoff serves as Vice President of Apple Tree Pharmaceuticals, which is an investor in Tokai Pharmaceuticals. No other disclosures are reported.
Funding/Support: The research was funded by the Dana-Farber Prostate Cancer SPORE P50CA090381 and by the Department of Defense (W81XWH-14-1-0515).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Correction: This article was corrected online May 21, 2015, for an error in the Methods section.